An Extension Study to Demonstrate the Equivalence of Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1

PHASE1CompletedINTERVENTIONAL

Enrollment

174

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions

Ankylosing Spondylitis

Interventions

BIOLOGICAL

Infliximab

CT-P13 (5mg/kg) administered as a 2-hour IV infusion per dose

Trial Locations (1)

Inha University Hospital, Incheon